The Department of Defense, through the Defense Health Agency, intends to award a sole source Firm-Fixed-Price contract to CERUS Corporation for the procurement of the INTERCEPT Blood System for Platelets. This system is a commercial-off-the-shelf (COTS) product essential for ensuring the safety and efficacy of platelet transfusions, which is critical for patient care in military medical facilities. The contract will cover a base year from January 1, 2025, to December 31, 2025, with an estimated total value of $210,816.00, and will include two option years. Interested parties may submit evidence demonstrating that competition would be beneficial to the Government, but the decision to proceed with a competitive procurement rests solely with the Government. For inquiries, contact Cynthia Scharnowske at cynthia.e.scharnowske.civ@health.mil, and please reference "Notice of Intent Submission 12160537" in the subject line.